GU Cancers 2024 | Treatment options for patients with UC who progress on chemotherapy and ICIs

Anand Sharma, MD, DPhil, MBBS, MRCP, Mount Vernon Cancer Centre, Northwood, UK, discusses treatment strategies for patients with urothelial carcinoma (UC) who progress on first-line checkpoint inhibitors (ICIs) and chemotherapy such as gemcitabine and cisplatin. Antibody-drug conjugates including sacituzumab govitecan and enfortumab vedotin, as well as FGFR inhibitors such as erdafitinib have shown promising results in clinical trials. Dr Sharma additionally highlights targeting HER2. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.